What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Antibody
- Immune system
His primary areas of investigation include Rheumatoid arthritis, Immunology, Arthritis, Tumor necrosis factor alpha and Cytokine.
His Rheumatoid arthritis study improves the overall literature in Internal medicine.
His Internal medicine research includes themes of Gastroenterology, Placebo and Surgery.
His studies link Alpha with Immunology.
His Tumor necrosis factor alpha research is multidisciplinary, relying on both Synovial Cell, Synovial membrane, Interleukin and Antibody, Monoclonal antibody.
His work carried out in the field of Cytokine brings together such families of science as Endocrinology, Synovial fluid, Molecular biology, Proinflammatory cytokine and Pharmacology.
His most cited work include:
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITIS (2251 citations)
- Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial (2178 citations)
- Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis (1592 citations)
What are the main themes of his work throughout his whole career to date?
Ravinder N. Maini mainly investigates Immunology, Rheumatoid arthritis, Antibody, Tumor necrosis factor alpha and Arthritis.
His Immunology study which covers Disease that intersects with Transplantation and Clinical trial.
His Rheumatoid arthritis study introduces a deeper knowledge of Internal medicine.
The various areas that he examines in his Antibody study include Gene and Antigen.
His Tumor necrosis factor alpha research incorporates themes from Inflammation, Proinflammatory cytokine, Pathology, Interleukin and Pharmacology.
His studies deal with areas such as Alpha and Immunotherapy as well as Arthritis.
He most often published in these fields:
- Immunology (61.26%)
- Rheumatoid arthritis (44.14%)
- Antibody (30.18%)
What were the highlights of his more recent work (between 2000-2020)?
- Immunology (61.26%)
- Rheumatoid arthritis (44.14%)
- Internal medicine (18.92%)
In recent papers he was focusing on the following fields of study:
Immunology, Rheumatoid arthritis, Internal medicine, Tumor necrosis factor alpha and Infliximab are his primary areas of study.
His Immunology study frequently draws connections to other fields, such as Disease.
Ravinder N. Maini combines subjects such as Methotrexate, Cytokine, Arthritis, Combination therapy and Necrosis with his study of Rheumatoid arthritis.
His Internal medicine study combines topics in areas such as Gastroenterology and MEDLINE.
His biological study spans a wide range of topics, including Inflammation, Proinflammatory cytokine and Complex disease.
In his study, Immunotherapy, Signs and symptoms, Adalimumab and Route of administration is inextricably linked to Etanercept, which falls within the broad field of Infliximab.
Between 2000 and 2020, his most popular works were:
- Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? (1184 citations)
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial (1031 citations)
- Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. (689 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Antibody
- Immune system
Ravinder N. Maini mostly deals with Rheumatoid arthritis, Tumor necrosis factor alpha, Arthritis, Infliximab and Immunology.
Rheumatoid arthritis is a subfield of Internal medicine that Ravinder N. Maini tackles.
Ravinder N. Maini usually deals with Internal medicine and limits it to topics linked to Surgery and Gastroenterology.
His study in Tumor necrosis factor alpha is interdisciplinary in nature, drawing from both Inflammation, Sustained remission and Cytokine.
His Immunology study incorporates themes from Angiogenesis and Disease.
The Antibody study combines topics in areas such as Chemokine and Systemic administration, In vivo.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
